Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+targets

131 Results

Sort By:

Treatment of fibrosis-associated pathologies through downstream TGF-β pathway inhibition

Value PropositionInhibits downstream signaling pathway of TGF-β signaling, reducing pleiotropic and off-target effects.Selectively targets tissue specific calpains, increasing efficacy as compared to current TGF-β signaling pathway inhibitory methods.Applicable to several disease models with specific focus on epithelial-to-mesenchymal transition pathologies....

Published: 5/9/2024 | Inventor(s): David Kim, Harry Dietz

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Fibrosis Disorders, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Fibrosis, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Cell-Permeable Protein Therapeutic for Pain and Itch

Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...

Published: 5/9/2024 | Inventor(s): Hao-Jui Weng, Xinzhong Dong

Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain

Regeneration of cardiac muscle for the treatment of heart failure

Value Proposition:This technology provides a therapeutic approach for the regrowth of permanently damaged heart muscle.This could improve health outcomes for patients with severe heart failure.Technology DescriptionResearchers at Johns Hopkins have discovered that the manipulation of circadian genes can induce the proliferation and regeneration of cardiomyocytes...

Published: 5/10/2024 | Inventor(s): Emmanouil Tampakakis

Keywords(s):

Category(s): Clinical and Disease Specializations > Cardiovascular, Clinical and Disease Specializations > Cardiovascular > Heart Failure, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Targets

DNA methylation markers for metastatic prostate cancer

Value Proposition:· Detection of methylation patterns that are linked to prostate cancer development in an individual.· Enable development of a personalized treatment plan for individuals with aggressive prostate cancer.· Simultaneous determination of gene methylation and copy number. Technology DescriptionResearchers at Johns Hopkins...

Published: 5/9/2024 | Inventor(s): George Bova, William Nelson, Martin Aryee, William Isaacs, Srinivasan Yegnasubramanian

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Epigenetic, In Vitro Diagnostics, Mechanism-of-action Biomarker, Methylation, Prostate Cancer, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Diagnostic and Treatment Target for Checkpoint Inhibitor Pneumonitis

Unmet Need Checkpoint inhibitor pneumonitis (CIP) can develop as a complication of cancer immunotherapy and is the leading cause of treatment-related death. CIP incidence will continue to rise as immunotherapy treatments become more widespread. However, there are no reliable biomarkers for CIP diagnosis or prognosis. Current approaches for CIP management...

Published: 5/10/2024 | Inventor(s): Karthik Suresh, Mohammad Ghanbar, Franco D'alessio

Keywords(s):

Category(s): Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets

Hexosamine Analogs for Regenerative Medicine and Diseases Associated with the Musculoskeletal System

Unmet Need:Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 32.5 million adults in the United States, with an increasing incidence as the population ages (see CDC) . OA is associated with considerable morbidity as a consequence of joint damage, resulting in pain, loss of joint range of motion, and disability. The disease...

Published: 5/9/2024 | Inventor(s): Kevin Yarema, Jennifer Elisseeff, Jeannine Coburn, Udayanath Aich

Keywords(s): Antagonists/Inhibitors, Arthritis, Biologics, Carbohydrates, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Joint Disorders, Novel, Osteoarthritis, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Rheumatology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Rheumatology > Arthritis, Clinical and Disease Specializations > Rheumatology > Osteoarthritis

Albumin-Flt3L Fusion Protein to Enhance Anti-Tumor Immunity and Antigen-specific T-cell Cytotoxicity

Unmet Need: Active immunotherapy, such as anti-PD-1/PD-L1 and anti-CTLA-4 checkpoint blockage, involves the administration of molecules to mobilize host immune cells to recognize and kill tumors. Proper presentation of tumor antigens through antigen presenting cells is a prerequisite to elicit a potent immune response. Current strategies enhance antigen...

Published: 5/9/2024 | Inventor(s): T.c. Wu, Chien-Fu Hung, Brandon Lam

Keywords(s): Biologics, Cancers, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Research Instrument, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Clinical and Disease Specializations > Immunology, Technology Classifications, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Targets

Genetic Alterations in Medulloblastomas - MLL Genes as Targets for Diagnosis and Therapeutics

Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations,...

Published: 5/9/2024 | Inventor(s): Xiaosong Zhang, Hai Yan, Gregory Riggins, Victor Velculescu, Kenneth Kinzler, Darell Bigner, Nickolas Papadopoulos, Donald Parsons, Sian Jones, Rebecca Leary, Meng Li, Bert Vogelstein

Keywords(s): Biomarker, Brain Cancer, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Medulloblastoma, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Medulloblastoma

N-Hydroxysulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors

Technology OverviewThe invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide...

Published: 5/9/2024 | Inventor(s): Andrew Cohen, Frederick Brookfield, Vincent Kalish, Stephen Courtney, Lisa Frost, John Toscano

Keywords(s): Cardiovascular Diseases, Congestive Heart Failure, Congestive Heart Failure (CHF), Disease Indication, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Congestive Heart Failure

N-Substituted Hydroxylamine Derivatives with Carbon-Based Leaving Groups as Physiologically Useful Nitroxyl (HNO) Donors

Technology OverviewThe disclosed subject matter provides certain N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions...

Published: 5/9/2024 | Inventor(s): Daryl Guthrie, John Toscano

Keywords(s): Cardiovascular Diseases, Disease Indication, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

1 2 3 4 5 6 7 8 9 10 ...